Skip to main content

Advertisement

Table 3 Frequency, detailed combination patterns, progression-free survival, overall survival and response to first-generation TKIs of compound EGFR mutations

From: First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience

Subgroup of compound EGFR mutations Frequency (n,  %) Mutated exons Response (rate, %) PFS (range, months) OS (range, months)
Double common 5 (4.7)   25.0% 10.1 ± 2.4 24.2 ± 8.2
 19Del + L858R 5 19 and 21 3PR, 1SD, 1PD 4.9–12 13.1–25.6
Common + rare 11 (10.4)   45.5% 10.5 ± 3.9 Not reached
 19Del + L861Q 2 19 and 21 1PR, 1SD 11.9–14.4 26.5–41.2
 L858R + S720P 1 21 and 18 PD 2.1 2.1
 L858R + K757R 1 21 and 19 PR 9.0 8.7
 L858R + I744 M 1 21 and 19 PR 17.6 41.2
 L858R + S768I 3 21 and 20 1PR, 1PD, 1SD 1.8–6.2 4.0–12.5
 L858R + R776H 1 21 and 20 PR 10.5 12.6
 L858R + L858Q 1 21 and 21 NE 1 3
 L858R + L833V 1 21 and 21 SD 5.0 15.9
Common + T790M 69 (65.1)   56.5% 10.3 ± 0.6 Not reached
 19Del + T790M 43 19 and 20 27PR, 12SD, 2 PD, 2NE 0.6–40.7 0.2–88.5
 L858R + T790M 26 21 and 20 12PR, 10SD, 3PD, 1NE 0.9–24.1 1.2–56.6
Rare + rare 13 (12.3)   38.5% 6.5 ± 1.3 Not reached
 G719C + S768I 1 18 and 20 PR 6.5 13.2
 G719S + S768I 2 18 and 20 1PR, 1SD 1–8.0 2.0–8.4
 G719S + L858Q 1 18 and 21 SD 6.4 29.3
 G719X + S768I 3 18 and 20 2PR, 1SD 2.0–18 2.0–44.0
 G719X + L858Q 3 18 and 21 1SD, 1PD, 1NE 0.3–27.3 2.3–29.2
 G719S + E709A 1 18 and 18 PR 4.1 4.1
 G719S + L858Q 1 18 and 21 SD 6.4 29.3
 S768I + V774M 1 20 and 20 PD 2.0 13.8
Rare + T790M 8 (7.5%)   37.5% 5.4 ± 2.5 23.8 ± 1.5
 G719X + T790M 1 18 and 20 PR 11.1 55.6
 D761Y + T790M 2 19 and 20 2PD 1.1–5.5 1.1–8.5
 L858Q + T790M 5 21 and 20 2PR, 1SD, 2PD 1.4–20.6 18–88.3
  1. TKI tyrosine kinase inhibitor, PFS progression-free survival, OS overall survival, PR partial response, SD stable disease, CR complete response, PD progressive disease, NE not evaluated